The effect of Liraglutide on clinical and paraclinical symptoms in patients with polycystic ovary syndrome

Phase 2

Recruiting

• Conditions: Poly cystic ovary syndrom.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20220720055510N1
• Lead Sponsor: Shahre-kord University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 35

Inclusion Criteria

Women with polycystic ovary syndrome between the ages of 18 and 45 years,
Written and oral consent is obtained from patients to participate in the study
Do not have chronic physical diseases (except polycystic ovary syndrome) and mental diseases.
According to the patient, there is no long-term use of drugs.
Body mass index is more than 25 kg/m2.

Exclusion Criteria

Smoke.
suffering from other causes of hyperandrogenism such as congenital adrenal hyperplasia, Cushing's syndrome, ovarian or adrenal tumor.
Taking drugs that lead to side effects such as menstrual disorders, hirsutism or acne, or affect the profile of fat or blood sugar in the last 3 months, such as OCP, thiazides, corten, metformin, etc.
be pregnant.
Menopause
Have a history of previous pancreatitis.
Have a family history of medullary thyroid carcinoma (mtc).

Study & Design

• Study Type: interventional
• Study Design: Not specified